Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience

• Published in: Diagnostics (Basel) 2024-02, Vol.14 (5), p.502
• Main Authors: Ju, Hyunjin, Seok, Jin Myoung, Chung, Yeon Hak, Jeon, Mi Young, Lee, Hye Lim, Kwon, Soonwook, Kim, Sunyoung, Min, Ju-Hong, Kim, Byoung Joon
• Format: Article
• Language: English
• Subjects: Antibodies; autoimmune diseases of the nervous system; Biopharmaceutics; Care and treatment; COVID-19; COVID-19 vaccines; Disease; Drug dosages; Enzyme-linked immunosorbent assay; Enzymes; Health aspects; Health care industry; Immune system; Immunoglobulin G; Immunoglobulins; immunomodulating agents; immunosuppressive agents; Infections; Mortality; mRNA vaccines; Multiple sclerosis; Myasthenia gravis; Patients; RNA; Severe acute respiratory syndrome coronavirus 2; Vaccination
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14050502

This study evaluates the antibody responses to SARS-CoV-2 vaccines in patients with neuroimmunological disorders (pwNID) who are receiving immunomodulating treatments, compared to healthy individuals. It included 25 pwNID with conditions such as optic neuritis, neuromyelitis optica spectrum disorder, multiple sclerosis, myasthenia gravis, and polymyositis, as well as 56 healthy controls. All participants had completed their full SARS-CoV-2 vaccination schedule, and their blood samples were collected within six months of their last dose. The concentration of anti-SARS-CoV-2 IgG antibodies was measured using an enzyme-linked immunosorbent assay. The results showed that pwNID had significantly lower antibody titers (58.4 ± 49.2 RU/mL) compared to healthy individuals (81.7 ± 47.3 RU/mL). This disparity persisted even after adjusting for age and the interval between the final vaccination and sample collection. A notable correlation was found between the use of immunomodulating treatments and reduced antibody levels, whereas mRNA vaccines were linked to higher antibody concentrations. The conclusion of this study is that immunomodulating treatments may reduce the effectiveness of SARS-CoV-2 vaccines in pwNID. This insight is crucial for healthcare providers in designing vaccination strategies and managing treatment plans for pwNID on immunomodulating therapies, highlighting the need for personalized approaches in this subgroup.